Prospective clinical trials are mandatory to evaluate the sensitivity and accuracy of leukocyte ADAM17, nSMase2 or TNFα mRNA and STING levels to personalize dietary Bβglucans interventions for efficacious systemic, renal and vascular protection in the general population and to attenuate CKD progression and the initiation of medial calcium deposition in human CKD. The gene discussed is TNF; the disease is chronic kidney disease.